A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients

NCT00304616 Phase 4 COMPLETED

To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration

Details

Lead sponsor	Korea Otsuka Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	COMPLETED
Enrolment	500
Start date	2004-10
Completion	2007-10

Conditions

• Schizophrenia

Interventions

• Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone

Primary outcomes

• CGI-I mean score(at week 1, 3, 4, 8 & every 4 weeks until week 26)

Countries

South Korea